Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Harvard BioscienceFRA:HBI0 53 Days Inventory is 200.44 as of Jun. 2026, which is 11% above its 10-year median of 180.55. GuruFocus rates FRA:HBI0 with a GF Score™ of 53/100 and a GF Value™ of €6.70. The stock has 9 warning signs investors should review. Among 786 Medical Devices & Instruments companies, Harvard Bioscience ranks worse than 64.76% on this metric.
The historical rank and industry rank for Harvard Bioscience's Days Inventory or its related term are showing as below:
FRA:HBI0'
s Days Inventory Range Over the Past 10 Years
Min: 132.88 Med: 180.55 Max: 222.33
Current: 216.77
During the past 13 years, Harvard Bioscience's highest Days Inventory was 222.33. The lowest was 132.88. And the median was 180.55.
FRA:HBI0's Days Inventory is ranked worse than 64.76% of 786
companies
in the Medical Devices & Instruments industry
Industry Median: 176.445
vs FRA:HBI0: 216.77
Harvard Bioscience's Days Inventory
declined
from Jun. 2025 (238.42) to Jun. 2026 (200.44).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Harvard Bioscience's Inventory Turnover for the
three
months ended in Jun. 2026 was 0.46.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Harvard Bioscience's Inventory-to-Revenue for the
three
months ended in Jun. 2026 was 0.98.
Harvard Bioscience (FRA:HBI0) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Harvard Bioscience's Inventory Turnover for the
three
months ended in Jun. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Harvard Bioscience's Inventory to Revenue for the
three
months ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Harvard Bioscience Days Inventory Related Terms
Harvard Bioscience Days Inventory Historical Data
* Premium members only.
The historical data trend for Harvard Bioscience's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:HBI0 vs RVP, MLSS, ZJYL: Days Inventory Comparison
For the Medical Instruments & Supplies subindustry, Harvard Bioscience's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harvard Bioscience Days Inventory vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Harvard Bioscience's Days Inventory distribution charts can be found below:
* The bar in red indicates where Harvard Bioscience's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harvard Bioscience (FRA:HBI0) has a Days Inventory of 200.44 as of Jun. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Harvard Bioscience and its competitors. This is 11% above median its historical median of 180.55. Over the past decade, Harvard Bioscience's Days Inventory has ranged from 132.88 to 222.33. According to the industry distribution chart, Harvard Bioscience ranks #509 out of 786 companies in the Medical Devices & Instruments industry, placing it in the top 64.8%.
Is Harvard Bioscience's Days Inventory too high?
Harvard Bioscience's current Days Inventory of 200.44 is 11% above median its 10-year median of 180.55. Over the past 10 years, this metric has ranged from a low of 132.88 to a high of 222.33. The Medical Devices & Instruments industry median Days Inventory is 176.45. Harvard Bioscience's value of 200.44 is 13.6% above this industry median. Based on the distribution chart, Harvard Bioscience ranks #509 out of 786 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Harvard Bioscience has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Harvard Bioscience's Days Inventory compare to RVP and MLSS?
According to the Medical Devices & Instruments industry distribution chart, Harvard Bioscience ranks #509 out of 786 companies for Days Inventory. This places Harvard Bioscience in the lower half of its industry. The industry median Days Inventory is 176.45. Harvard Bioscience's value of 200.44 is 13.6% above this benchmark. Historically, Harvard Bioscience's own Days Inventory has ranged from 132.88 to 222.33 over the past decade. While the company's 10-year median is 180.55 vs. the industry median of 176.45, Harvard Bioscience has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Devices & Instruments company?
The median Days Inventory among Medical Devices & Instruments companies is 176.45, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Harvard Bioscience's current Days Inventory of 200.44 is 13.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Harvard Bioscience and its competitors. For the Medical Devices & Instruments industry, the median Days Inventory is 176.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harvard Bioscience's current Days Inventory is 200.44, which is 11% above median its own 10-year median of 180.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harvard Bioscience stock overvalued right now?
Harvard Bioscience (FRA:HBI0) has a current Days Inventory of 200.44. The stock's GF Value™ is €6.70, compared to a current price of €4.08 — trading 39.1% below its estimated fair value. The current Days Inventory is 200.44, which is 11% above median its 10-year median of 180.55 and 13.6% above the Medical Devices & Instruments industry median of 176.45. Harvard Bioscience's overall GF Score™ is 53/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Harvard Bioscience (FRA:HBI0), the current Days Inventory is 200.44 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harvard Bioscience (FRA:HBI0) Overvalued in 2026?
Based on GuruFocus' analysis, Harvard Bioscience stock appears to be undervalued.
The current stock price of €4.08 is trading 39.1% below its estimated GF Value™ of €6.70.
Key valuation signals for FRA:HBI0:
Days Inventory: 200.44 (11% above median its 10-year median of 180.55)
GF Value™: €6.70 vs. price of €4.08 (39.1% below fair value)
Industry Position: 13.6% above the Medical Devices & Instruments median (#509 of 786)
No single metric tells the full story. See the FRA:HBI0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
53GF Score
Get the complete analysis for FRA:HBI0
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:HBI0 has been successfully added to your 
